{"id":"W3033907870","doi":"10.1186/s13045-020-00900-7","title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Genentech; H. Lundbeck A/S; Juno Therapeutics; Incyte; F. Hoffmann-La Roche; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; Servier; TG Therapeutics; Amgen","keywords":"Obinutuzumab; Rituximab; Medicine; Internal medicine; Hematology; Diffuse large B-cell lymphoma; Oncology; CHOP; Lymphoma; Vincristine; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006823672,0.0003502483,0.006402831,0.0006871106,0.00005188993,0.00001064326,0.0003753749,0.0002348603,0.0001305623],"category_scores_gemma":[0.0003773008,0.0002080914,0.0002986403,0.00118899,0.0002047533,0.0001342807,0.0001782371,0.0002140067,0.000004268319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008378341,"about_ca_system_score_gemma":0.001767765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003838913,"about_ca_topic_score_gemma":0.0006525065,"domain_scores_codex":[0.9957281,0.0007866988,0.002253253,0.0003866876,0.0004299744,0.0004152658],"domain_scores_gemma":[0.9954468,0.0009304337,0.002413071,0.0003443029,0.0005786264,0.0002867452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6188738,0.2113522,0.1496454,0.0001392242,0.009547419,0.004502116,0.004691429,0.00002704609,0.00001615316,0.00006456648,0.0003696248,0.0007709473],"study_design_scores_gemma":[0.9304802,0.04060558,0.01054428,0.000143145,0.01550658,0.0003192996,0.001197056,0.0006644366,0.0002290983,0.000004398506,0.0001553711,0.0001505179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958908,0.0008771453,0.00003343269,0.0005375788,0.0000690715,0.002353009,0.00002926316,0.000008190568,0.0002015001],"genre_scores_gemma":[0.998602,0.0001853757,0.0006079957,0.0003935914,0.00001988602,0.00009893473,0.00002784445,0.00002470771,0.00003962184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3116064,"threshold_uncertainty_score":0.8485721,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03923046234378376,"score_gpt":0.345590446810616,"score_spread":0.3063599844668322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}